Clinical Trial Update: Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating Envafolimab plus Endostar/S-1 in second-line advanced non-small cell lung cancer, focusing on effect and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Endostar (recombinant human endostatin)
• Envafolimab (envafolimab)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Anhui Chest Hospital | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: UNKNOWN